



**GlaxoSmithKline Pharmaceuticals Ltd.**

GSK House,  
Dr. Annie Besant Road, Worli,  
Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

29<sup>th</sup> October 2021

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sirs,

**Subject: Media release: Q2 of 2021-22**

Please find enclosed a press release issued by the Company in respect of financial results for the quarter ended 30<sup>th</sup> September 2021.

This is for your information and record.

Yours faithfully  
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151



---

## GSK delivers 13% sales growth for the quarter ended September 30, 2021

### Innovation and Specialty pipeline continues to reach more patients

---

**GlaxoSmithKline Pharmaceuticals Ltd** today declared its financial results for the quarter ended September 30, 2021. Revenue for the quarter came in at Rs 992 crores recording a growth of 13%. PBT (before exceptional) for the quarter at Rs 271 crores recorded a growth of 42%. EBITDA at Rs 274 crores recorded a growth of 34%.

Revenue for the six months ended September 30, 2021 was Rs 1765 crores recording a growth of 16%. PBT (before exceptional) for the six months at Rs 435 crores recorded a growth of 28%. EBITDA at Rs 425 crores recorded a growth of 33%.

Commenting on the results, **Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited**, said, "We delivered a strong performance in Q2. As the acute market showed signs of recovery, our established brands grew in their respective therapeutic portfolios. *Augmentin* and *Calpol* regained their place amongst the top five brands in the Indian Pharmaceuticals Market (IPM). Our promoted portfolio also gained market share, while products from our innovation and specialty pipeline continued to make inroads to serve more patients.

We continue to find ways to leverage innovations in emerging technologies and deliver even greater value to our shareholders in alignment with our priorities. We also improved our operational efficiencies, driven by sales growth and cost rationalisation. We also improved our cash position backed by working capital improvements. We expect this positive momentum to continue through the second half of the year driving us towards the better end of a meaningful performance improvement. Our clear priority is to focus on execution, unlocking the value for patients and delivering step change growth and performance."

#### About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit [www.gsk-india.com](http://www.gsk-india.com)

#### Media Contact

Ransom D'Souza  
Communications and Government Affairs  
Email: [ransom.a.dsouza@gsk.com](mailto:ransom.a.dsouza@gsk.com)